OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Levels of house dust mites (HDM) in homes of patients with bronchial asthma (BA) and the airway inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 281s Year: 2001
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
Concentration of house dust mites, respiratory symptoms and atopy markers Source: Eur Respir J 2005; 26: Suppl. 49, 680s Year: 2005
Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Exhaled NO in steroid naive house dust mite allergic asthmatics Source: Eur Respir J 2007; 30: Suppl. 51, 617s Year: 2007
Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
Association between house dust mites (HDM) level in homes of atopic children and interleukine-4 and IgE in expired air condensate(EAC) Source: Eur Respir J 2002; 20: Suppl. 38, 536s Year: 2002
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Exposure to higher levels of house dust mite allergen and endotoxin is not associated with respiratory symptoms and severity of AHR in older asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 454s Year: 2002
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Models to mimic allergic asthma using house dust mite or Aspergillus fumigatus in mice: advantages and disadvantages Source: Annual Congress 2005 - PG11 - Experimental models for COPD and asthma Year: 2005
The reduction of the house dust mite as a prevention component in a treatment of the asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 335s Year: 2002
The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006
Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001